Biocompatible denatured albumin lamina

Abstract

The present invention provides a denatured albumin lamina, useful for repairing lesions on solid visceral organs. The lamina comprises human serum albumin, formed into a thin, pliant sheet and denatured. The denatured lamina can be sterilized and stored until used. As well, it can be impregnated with a variety of bioagents. A method for repairing a lesion on a solid visceral organ includes applying an energy-absorbing proteinaceous material to a lesion site on the solid visceral organ lesion; irradiating the proteinaceous material with energy sufficient to fuse the energy-absorbing material at least partially to the lesion site; applying a biocompatible denatured albumin lamina onto the proteinaceous material on the lesion site; and irradiating the biocompatible albumin lamina and the proteinaceous material with energy sufficient to fuse the biocompatible albumin lamina to the proteinaceous material and/or the lesion site. A laser solder can be deployed beneath the lamina to aid in welding it to the organ surface using laser light energy.

1. A method of repairing a lesion on a solid visceral organ, comprising:
 applying an energy-absorbing proteinaceous solder material to a lesion site on the solid visceral organ lesion; 
 irradiating the proteinaceous material with energy sufficient to fuse the energy-absorbing material at least partially to the lesion site; 
 applying a scaffold comprising a biocompatible denatured albumin lamina onto the proteinaceous material on the lesion site; and 
 subsequent to applying the biocompatible denatured albumin lamina onto the proteinaceous material, irradiating the biocompatible denatured albumin lamina and the proteinaceous material with energy sufficient to fuse the biocompatible denatured albumin lamina to the proteinaceous material and&orand/or the lesion site. 
 
     
     
       2. The method of  claim 1 , wherein the biocompatible albumin lamina is irradiated sufficiently to reduce hemorrhage at the lesion site by at least 50%. 
     
     
       3. The method of  claim 1 , wherein the biocompatible denatured albumin lamina has an albumin concentration of about above 50% to 58% 57% prior to being manufactured into a denatured albumin lamina. 
     
     
       4. The method of  claim 1 , further comprising:
 clamping off blood supply to the lesion site of the solid visceral organ. 
 
     
     
       5. The method of  claim 1 , wherein the proteinaceous solder material is fluidic and is applied to a thickness of 100-1000 μm. 
     
     
       6. The method of  claim 1 , wherein the energy-absorbing material comprises a chromophore and the energy is light energy of a wavelength absorbed by the chromophore to fuse the biocompatible albumin lamina to the lesion site. 
     
     
       7. The method of  claim 6 , wherein the biocompatible albumin lamina is translucent to light energy. 
     
     
       8. The method of  claim 5 , wherein the proteinaceous material is fluidic and is applied to a thickness of 100-250 μm. 
     
     
       9. The method of  claim 1  wherein the biocompatible denatured albumin la lamina contains sufficient water content to be pliable and has a thickness in a range of 75 μm to 300 μm. 
     
     
       10. The method of  claim 8  wherein the albumin lamina has a thickness of about 250 μm. 
     
     
       11. The method of  claim 1  wherein the albumin lamina has a tensile strength of at least about 625 kPa. 
     
     
       12. The method of  claim 1  wherein the albumin lamina has an elasticity of about 1700 kPa to 4000 kPa. 
     
     
       13. The method of  claim 1  wherein the albumin lamina contains a chromophore. 
     
     
       14. The method of  claim 6  wherein the chromophore is indocyanine green. 
     
     
       15. The method of  claim 1  wherein the albumin lamina contains at least one biologically active agent. 
     
     
       16. The method of  claim 1 , wherein the biocompatible albumin lamina is irradiated sufficiently to reduce hemorrhage at the lesion site by 50-90%. 
     
     
       17. The method of  claim 1 , wherein the biocompatible denatured albumin lamina comprises human serum albumin formed into a thin, pliant sheet prior to being manufactured into a denatured albumin lamina. 
     
     
       18. The method of claim 3, wherein the biocompatible denatured albumin lamina has an albumin concentration in the range from 53% to 55% prior to being manufactured into a denatured albumin lamina.